NCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
Clinical Trials
8 trialsNCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT00268385 2026-04-13
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05096481 2026-04-08
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05413304 2026-03-24
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT06413706 2026-03-24
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
Phase 2 Active not recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting